- Home
- TALO vs HCM Comparison
TALO vs HCM Comparison
Compare TALO & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | HCM |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TALO | HCM |
|---|---|---|
| Price | $14.88 | $15.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $21.56 | $21.14 |
| AVG Volume (30 Days) | ★ 3.9M | 42.6K |
| Earning Date | 11-03-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,780,070,000.00 | N/A |
| Revenue This Year | $31.27 | $14.11 |
| Revenue Next Year | $2.19 | $11.97 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.15 | $9.77 |
| 52 Week High | $18.76 | $16.33 |
Technical Indicators
Market Signals| Indicator | TALO | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 64.55 |
| Support Level | $14.30 | $13.00 |
| Resistance Level | $15.96 | $15.55 |
| Average True Range (ATR) | 0.83 | 0.39 |
| MACD | -0.39 | 0.17 |
| Stochastic Oscillator | 17.98 | 93.50 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.